Skip to main content

Adverum Biotechnologies to Present New Data from the OPTIC Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at ARVO 2021 

Written by Customer Service on . Posted in Public Companies.

— Adverum to host webcast with key opinion leaders on Sunday, May 2, 2021 at 7:00 AM PT — 

REDWOOD CITY, Calif., April 16, 2021 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of additional clinical data for Cohorts 1-4 in the OPTIC clinical trial of ADVM-022 intravitreal (IVT) injection gene therapy in wet age-related macular degeneration (wet AMD) during the Association for Research in Vision and Ophthalmology (ARVO) 2021 Virtual Meeting. Preclinical data on ADVM-062, a novel IVT gene therapy that also utilizes Adverum’s proprietary vector capsid AAV.7m8, in blue cone monochromacy will also be presented.

Presentation Title: Phase 1 Study of Intravitreal Gene Therapy with ADVM-022 for Neovascular AMD (OPTIC Trial)  
Session: AMD: Clinical research – New Therapies and Technologies  
Date and Time: May 3, 2021 from 4:30 PM to 6:00 PM ET  
Presenter: Brandon G. Busbee, M.D., partner, Tennessee Retina Physicians 

Poster Title: Preclinical Evaluation of ADVM-062, a Novel Intravitreal Gene Therapy for the Treatment of Blue Cone Monochromacy  
Session: Drug Delivery and Gene Therapy  
Date and Time: May 3, 2021 from 11:15 AM to 1:00 PM ET 
Presenter: Ruslan Grishanin, director translational science, Adverum Biotechnologies 

On Saturday, May 1, 2021 at 7:00 AM ET, the virtual presentations will be available on demand to ARVO participants. Adverum plans to post the ADVM-022 OPTIC presentation under Events and Presentations in the Investors section of Adverum’s website. The ADVM-062 BCM poster will be available in the Publications section of Adverum’s website. 

Adverum Webcast
Date: May 2, 2021 
Time: 7:00 – 8:30 AM PT (10:00 – 11:30 AM ET)
Key Opinion Leaders Participating: 

  • Brandon G. Busbee, M.D.​, partner, Tennessee Retina Physicians; Investigator in OPTIC ​
  • Jeffrey S. Heier, M.D.​, director of the Vitreoretinal Service and director of Retina Research at Ophthalmic Consultants of Boston

The live video webcast will be accessible under Events and Presentations in the Investors section of Adverum’s website. To participate in the conference call, dial 1-877-705-6003 (domestic) or 1-201-493-6725 (international) and refer to the “Adverum Biotechnologies’ OPTIC Clinical Data Discussion Conference Call.” It is recommended call participants dial in 15 minutes in advance. The archived audio webcast will be available on Adverum’s website following the call and will be available for 30 days. 

On May 6, 2021 after market, Adverum plans to report recent business progress and financial results for the first quarter of 2021.

About Adverum Biotechnologies
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema. For more information, please visit www.adverum.com.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.